Treatment of Ocular Melanoma with Fotemustine and Immunotherapy
Author Information
Author(s): Becker J C, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker E-B
Primary Institution: University of Würzburg, Germany
Hypothesis
The study aimed to evaluate the effectiveness of a combination therapy of fotemustine, interleukin 2, and interferon α in patients with metastatic ocular melanoma.
Conclusion
The combination therapy showed some therapeutic activity, with a median overall survival of about one year, which is better than previously reported for non-fotemustine treatments.
Supporting Evidence
- Objective responses were more frequent in the intraarterial fotemustine group (21.7%) compared to the intravenous group (8%).
- The median overall survival for patients receiving intraarterial fotemustine was 369 days.
- Patients with stable disease experienced a median progression-free survival of almost one year.
- Only one patient achieved a complete response, while six achieved a partial response.
Takeaway
Doctors tried a new treatment for eye cancer that spreads to the liver, and it helped some patients live longer.
Methodology
Forty-eight patients received fotemustine followed by immunotherapy with interleukin 2 and interferon α, with treatment tailored based on the presence of liver and extrahepatic metastases.
Potential Biases
The lack of randomization may introduce selection bias in treatment outcomes.
Limitations
The study was not randomized, and the treatment arms were stratified based on the presence of extrahepatic metastases.
Participant Demographics
Approximately 60% of the participants were women, with a median time of almost 3 years from primary diagnosis to metastasis.
Statistical Information
P-Value
0.0058
Confidence Interval
95% confidence interval, 6.1 to 28.4%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website